Financings roundup: Genomic Health’s IPO gathers $60M for breast cancer test Oct. 6, 2005 By Jennifer Boggs
CancerVax Tumbles On Poor Canvaxin Data, Cuts 100 Jobs Oct. 5, 2005 By Jennifer Boggs Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)Read More
